N | Total 608 | Prostate-cancer-specific death 48 | HR | (95 % CI) | AHRa | (95 % CI) | |
---|---|---|---|---|---|---|---|
Variables | N (%) | N | |||||
Hair dyes | |||||||
No | 443 | (72.9) | 35 | 1.00 | 1.00 | ||
Yes | 161 | (54.4) | 13 | 0.89 | (0.45-1.65) | 1.14 | (0.47-2.59) |
Missing | 4 | 0 | |||||
Years of use | |||||||
Never | 443 | (72.9) | 35 | 1.00 | 1.00 | ||
≤10 years | 85 | (14.0) | 9 | 1.16 | (0.52-2.31) | 1.46 | (0.54-3.56) |
>10 years | 64 | (10.5) | 2 | 0.35 | (0.06-1.15) | 0.33 | (0.02-1.74) |
Missing | 16 | 2 | |||||
Frequency of use (times per year | |||||||
Never | 443 | (72.9) | 35 | 1.00 | 1.00 | ||
≤6 | 83 | (13.7) | 5 | 0.75 | (0.26-1.74) | 0.62 | (0.14-1.94) |
>6 | 63 | (10.4) | 7 | 1.07 | (0.43-2.28) | 2.15 | (0.70-6.03) |
Missing | 19 | 1 | |||||
Regular exercise | |||||||
No | 252 | (41.4) | 34 | 1.00 | 1.00 | ||
Yes | 353 | (58.1) | 14 | 0.27 | (0.14-0.50)* | 0.37 | (0.16-0.83)* |
Missing | 3 | 0 | |||||
Frequency of exercise (times per week) | |||||||
Never | 252 | (41.4) | 34 | 1.00 | 1.00 | ||
1-6 | 161 | (26.5) | 7 | 0.34 | (0.14-0.73)* | 0.66 | (0.22-1.82) |
≥7 | 188 | (30.9) | 6 | 0.20 | (0.08-0.45)* | 0.23 | (0.07-0.65)* |
Missing | 7 | 1 | |||||
Clinical stageb | |||||||
Localized | 290 | (47.7) | 7 | 1.00 | 1.00 | ||
Locally advanced | 158 | (26.0) | 7 | 1.95 | (0.67-5.71) | 1.56 | (0.41-5.69) |
Bone metastasis | 154 | (25.3) | 34 | 12.10 | (5.64-29.99)* | 10.15 | (3.22-35.98* |
Missing | 6 | 0 |